Sehayek E - Search Results

1

Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia.

Leitersdorf E, Eisenberg S, Eliav O, Berkman N, Dann EJ, Landsberger D, Sehayek E, Meiner V, Peters TK, Muratti EN, et al. Leitersdorf E, et al. Among authors: sehayek e. Eur J Clin Pharmacol. 1993;45(6):513-8. doi: 10.1007/BF00315307. Eur J Clin Pharmacol. 1993. PMID: 8157036 Clinical Trial.

2

Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.

Leitersdorf E, Muratti EN, Eliav O, Meiner V, Eisenberg S, Dann EJ, Sehayek E, Peters TK, Stein Y. Leitersdorf E, et al. Among authors: sehayek e. Am J Med. 1994 May;96(5):401-7. doi: 10.1016/0002-9343(94)90165-1. Am J Med. 1994. PMID: 8192170 Clinical Trial.

3

Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.

Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, Landsberger D, Sehayek E, Meiner V, Wurm M, et al. Leitersdorf E, et al. Among authors: sehayek e. Circulation. 1993 Apr;87(4 Suppl):III35-44. Circulation. 1993. PMID: 8462179 Clinical Trial.

4

Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.

Sehayek E, Eisenberg S. Sehayek E, et al. J Biol Chem. 1991 Sep 25;266(27):18259-67. J Biol Chem. 1991. PMID: 1917954 Free article.

5

Abnormal composition of hypertriglyceridemic very low density lipoprotein determines abnormal cell metabolism.

Sehayek E, Eisenberg S. Sehayek E, et al. Arteriosclerosis. 1990 Nov-Dec;10(6):1088-96. doi: 10.1161/01.atv.10.6.1088. Arteriosclerosis. 1990. PMID: 2244857

6

Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors.

Sehayek E, Butbul E, Avner R, Levkovitz H, Eisenberg S. Sehayek E, et al. Eur J Clin Invest. 1994 Mar;24(3):173-8. doi: 10.1111/j.1365-2362.1994.tb00984.x. Eur J Clin Invest. 1994. PMID: 8033951

7

Disparate effects of a triglyceride lowering diet and of bezafibrate on the HDL system: a study in patients with hypertriglyceridaemia and low HDL-cholesterol levels.

Arnon R, Sehayek E, Eisenberg S. Arnon R, et al. Among authors: sehayek e. Eur J Clin Invest. 1993 Aug;23(8):492-8. doi: 10.1111/j.1365-2362.1993.tb00796.x. Eur J Clin Invest. 1993. PMID: 8405002

8

[Screening and treatment of hyperlipidemias in Israel].

Sehayek E, Eisenberg S. Sehayek E, et al. Harefuah. 1995 May 1;128(9):529-32, 600. Harefuah. 1995. PMID: 7797148 Hebrew.

9

Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix.

Eisenberg S, Sehayek E, Olivecrona T, Vlodavsky I. Eisenberg S, et al. Among authors: sehayek e. J Clin Invest. 1992 Nov;90(5):2013-21. doi: 10.1172/JCI116081. J Clin Invest. 1992. PMID: 1430223 Free PMC article.

10

Lipolysis exposes unreactive endogenous apolipoprotein E-3 in human and rat plasma very low density lipoprotein.

Sehayek E, Lewin-Velvert U, Chajek-Shaul T, Eisenberg S. Sehayek E, et al. J Clin Invest. 1991 Aug;88(2):553-60. doi: 10.1172/JCI115339. J Clin Invest. 1991. PMID: 1864965 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

62 results

Search Page

Filters